ArticleBritish journal of pharmacology2019
Cannabichromene is a cannabinoid CB
Article in British journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- A systematic review of minor phytocannabinoids with promising neuroprotective potential.British journal of pharmacology · 2020Pooled it
- Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and ΔEuropean journal of clinical pharmacology · 2022Trial
- Pharmacological Switching in Minor Phytocannabinoids: A Mechanistic Framework for Compound-Indication Matching and Precision Neurotherapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- On the use of open-label studies for the evaluation of cannabis-based products for the treatment of long COVID.British journal of clinical pharmacology · 2026Article
- Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.Antioxidants (Basel, Switzerland) · 2026Article
- Cannabidiol and other non-psychotropic cannabinoids from Cannabis sativa as therapeutics for microglial-mediated neuroinflammation and neurodegeneration.Journal of cannabis research · 2026Review
- The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.Current topics in behavioral neurosciences · 2026Review
- Modulation of cardiac contractility and redox balance via cannabinoid type II receptor activation in healthy rats.Pflugers Archiv : European journal of physiology · 2025Article
- Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model.Journal of clinical medicine · 2025Article
- Recreational drugs repurposed for medicinal use-cannabis.CNS spectrums · 2025Review
- New Cannabinoids and Chlorin-Type Metabolites from the Flowers ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Inflammaging and Immunosenescence in the Post-COVID Era: Small Molecules, Big Challenges.ChemMedChem · 2025Review
- Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity.Journal of pain research · 2025Article
- Pharmacology of Non-Psychoactive Phytocannabinoids and Their Potential for Treatment of Cardiometabolic Disease.Handbook of experimental pharmacology · 2025Review
- Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.International journal of molecular sciences · 2024Review
- The Potential of Cannabichromene (CBC) as a Therapeutic Agent.The Journal of pharmacology and experimental therapeutics · 2024Review
- Identification and Characterization of Cannabichromene's Major Metabolite Following Incubation with Human Liver Microsomes.Metabolites · 2024Article
- Combinations of Cannabinoids with Silver Salts or Silver Nanoparticles for Synergistic Antibiotic Effects against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Elucidating the Mechanism of Metabolism of Cannabichromene by Human Cytochrome P450s.Journal of natural products · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeCannabichromene (CBC) is one of the most abundant phytocannabinoids in Cannabis spp. It has modest antinociceptive and anti-inflammatory effects and potentiates some effects of Δ EXPERIMENTAL APPROACH: AtT20 cells stably expressing haemagglutinin-tagged human CB KEY
resultsCBC activated CB CONCLUSIONS AND IMPLICATIONS: CBC is a selective CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.